U.S. Missile Stockpiles Decrease, FDA Considers mRNA Flu Vaccine

Why it matters locally: While the primary impact of decreased missile stockpiles is national security, potential future federal defense spending shifts could indirectly affect Montana businesses involved in federal contracting. The FDA's decision on the mRNA flu vaccine will directly impact healthcare options available to Montana residents, with the Montana Department of Public Health and Human Services likely to guide local distribution if approved.

The U.S. Army's missile stockpiles have decreased, and officials estimate replenishment could require several years. This reduction in inventory comes as the Food and Drug Administration (FDA) considers approving a new flu vaccine that incorporates messenger RNA (mRNA) technology. Defense officials have indicated that current U.S. Army missile reserves have reached levels that necessitate a prolonged period for restoration. They project that rebuilding these stockpiles to previous capacities will take multiple years. Separately, the FDA is evaluating a flu vaccine developed with mRNA technology. This assessment will determine whether the vaccine meets regulatory standards for public use. The outcome of the FDA's review will dictate its availability.